Mitochondria play a central role in the intrinsic pathway of apoptosis. Oligomerization of the mitochondrial protein VDAC1 (voltage-dependent anion channel 1) has been proposed to play a role in apoptosis in various studies. In the present study, we have generated dimeric fusion proteins consisting of tandemlinked wild-type and RuR (Ruthenium Red)-insensitive mutant VDAC1 monomers and studied the capacity of RuR to protect against apoptosis, as induced by various means. Fusion proteins composed of wild-type and/or E72Q-VDAC1 were successfully expressed in T-REx-293 cells. Bilayer-reconstituted dimeric rVDAC1 (rat VDAC1) functions as a channel-forming protein, showing typical voltage-dependence conductance, but with a unitary conductance higher than that of monomeric VDAC. As with wild-type VDAC1, overexpression of either the wild-type or mutated VDAC1 dimeric fusion protein induced apoptotic cell death. In addition, as shown previously, the anti-apoptotic effect of RuR was not observed in cells expressing E72Q-VDAC1, despite endogenous VDAC1 being present in these cells. Similar RuR insensitivity governed the VDAC1 fusion proteins comprising the E72Q mutation in either the first, second or both VDAC1 monomers of the same dimer. RuRmediated protection against apoptosis in T-REx-293 cells, as induced by staurosporine, was observed in cells expressing VDAC1 or dimeric wild-type VDAC1. However, RuR offered no protection against staurosporine-induced apoptosis in cells expressing E72Q-VDAC1 or E72Q-containing dimeric VDAC1. These results suggest that E72Q-VDAC1 has a dominant-negative effect and implies that VDAC1 homo-oligomerization, involving intermolecular interactions, might be involved in the apoptotic process.
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Mitochondria play a central role in the intrinsic pathway of apoptosis. Oligomerization of the mitochondrial protein VDAC1 (voltage-dependent anion channel 1) has been proposed to play a role in apoptosis in various studies. In the present study, we have generated dimeric fusion proteins consisting of tandemlinked wild-type and RuR (Ruthenium Red)-insensitive mutant VDAC1 monomers and studied the capacity of RuR to protect against apoptosis, as induced by various means. Fusion proteins composed of wild-type and/or E72Q-VDAC1 were successfully expressed in T-REx-293 cells. Bilayer-reconstituted dimeric rVDAC1 (rat VDAC1) functions as a channel-forming protein, showing typical voltage-dependence conductance, but with a unitary conductance higher than that of monomeric VDAC. As with wild-type VDAC1, overexpression of either the wild-type or mutated VDAC1 dimeric fusion protein induced apoptotic cell death. In addition, as shown previously, the anti-apoptotic effect of RuR was not observed in cells expressing E72Q-VDAC1, despite endogenous VDAC1 being present in these cells. Similar RuR insensitivity governed the VDAC1 fusion proteins comprising the E72Q mutation in either the first, second or both VDAC1 monomers of the same dimer. RuRmediated protection against apoptosis in T-REx-293 cells, as induced by staurosporine, was observed in cells expressing VDAC1 or dimeric wild-type VDAC1. However, RuR offered no protection against staurosporine-induced apoptosis in cells expressing E72Q-VDAC1 or E72Q-containing dimeric VDAC1. These results suggest that E72Q-VDAC1 has a dominant-negative effect and implies that VDAC1 homo-oligomerization, involving intermolecular interactions, might be involved in the apoptotic process.
INTRODUCTION
Mitochondria are not only central to basic life functions, by being responsible for the generation of cellular energy, but also play a central role in the regulation of apoptosis (programmed cell death) and thus represent the venue for cellular decisions leading to cell life or death [1] . During transduction of the apoptotic signal into the cell, an alteration in mitochondrial permeability occurs, facilitating the release of the apoptogenic proteins, cytochrome c, AIF (apoptosis-inducing factor) and Smac (second mitochondrialderived activator of caspase)/DIABLO [direct IAP (inhibitor of apoptosis)-binding protein with low pI]. These proteins participate in complex processes, resulting in the activation of proteases and nucleases, in turn leading to DNA and protein degradation and ultimately to cell death [1, 2] .
VDAC1 (voltage-dependent anion channel 1), also known as mitochondrial porin, is the main channel protein of the OMM (outer mitochondrial membrane), controlling metabolic cross-talk between the mitochondrion and the rest of the cell [3, 4] . As such, down-regulation of VDAC1 expression via shRNA (small-hairpin RNA) leads to a decrease in energy production and inhibition of cell growth [5] .
There is substantial evidence suggesting that VDAC1 not only plays a crucial role in regulating the metabolic and energy functions of mitochondria but that it is also a key player in mitochondria-mediated apoptosis [6] . VDAC1 has been proposed to be part of the PTP (permeability transition pore), a putative multi-protein complex proposed to mediate mitochondrial permeability transition. VDAC1 was also suggested to function in the release of apoptogenic proteins located in the mitochondrial inter-membrane space to the cytosol, and to serve as the target of pro-and anti-apoptotic members of the Bcl2-family and HK (hexokinase) [4, [7] [8] [9] [10] [11] [12] [13] [14] . Evidence for VDAC1 involvement in apoptosis includes the capability of anti-VDAC1 antibodies to inhibit cytochrome c release and cell death, along with its interaction with the pro-apoptotic protein, Bax [15] [16] [17] . Moreover, the ability of HK to inhibit cytochrome c release and cell death was shown in cells expressing wild-type, but not mutated, VDAC1 [18] . Similarly, RuR (Ruthenium Red) interacts with wild-type, but not mutated VDAC1 in order to prevent cytochrome c release and cell death [10, 19] . Added to that, it was demonstrated recently that siRNA (small interfering RNA)-mediated down-regulation of VDAC1 prevented cell death induced by cisplatin and strongly reduced cisplatin-induced release of cytochrome c, AIF and maturation of caspase 3 [8] . Furthermore, depletion of VDAC1 strongly suppressed the cisplatin-induced activation of Bax [8] and reducing VDAC1 expression by siRNA also attenuated endostatin-induced apoptosis [9] . It has also been proposed that the action of well known drugs, like cisplatin [8] , FNQ13 [20] , methyl jasmonate [21] and erastin [22] , all selectively affect the viability of cancer cells through binding or other influences on VDAC1.
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Despite this body of work pointing to VDAC1 as a key player in apoptosis, major questions remain unsolved. The most pressing questions are how the mitochondrial pro-apoptotic proteins are released, how this event is regulated and what functions VDAC1 plays in these processes.
Recently, the topology and three-dimensional structure of recombinant hVDAC1 (human VDAC1) and mVDAC1 (murine VDAC1) were solved by NMR spectroscopy [23, 24] and X-ray crystallography [23, 25] . Apparently, VDAC1 adopts a β-barrel architecture comprising 19 β-strands with an α-helix N-terminal segment oriented against its interior wall, causing a partial narrowing at the centre of the ∼ 3 nm pore. The inner diameter of VDAC1 is thus large enough for the movement of nucleotides and small molecules, but too small to allow the passage of a folded protein, like cytochrome c.
The protein-conducting channel could form via a VDAC1 homo-oligomer or in hetero-oligomers containing VDAC1 and pro-apoptotic proteins [13, 15, 18, 26, 27] . Indeed, the supramolecular organization of VDAC1 has also been demonstrated using atomic force microscope [28, 29] and X-ray crystallography [30] . Moreover, we have found that apoptosis induction, by various stimuli, is accompanied by increased VDAC1 oligomerization [31] [32] [33] . Similarly, the apoptosis-inducing effect of As 2 O 3 (arsenic trioxide) was attributed to the generation of VDAC1 homodimers, which was prevented by overexpression of the anti-apoptotic protein, Bcl-XL [17] ; As 2 O 3 also induces Bax and VDAC1 oligomerization [34] . It was further demonstrated that VDAC1 oligomerization is encouraged in the presence of cytochrome c [27] . Our finding that VDAC1 can exist as oligomers led us to propose that oligomeric VDAC1 mediates the release of cytochrome c [13, 18, 27, 32, 33, 35] .
To further support the involvement of VDAC1 oligomerization in mitochondria-mediated apoptosis, we have used the E72Q-VDAC1 mutant, a version of the protein that has lost its capacity to bind to HK [18, 19] and RuR [10, 19] , and hence cannot confer protection against apoptosis. In intact cells, RuR was shown to slowly cross the plasma membrane and prevent cell death induced by various stimuli in different cell lines [19, [36] [37] [38] . Such protection was prevented when VDAC1 was mutated at Glu 72 or Glu 202 [10, 19] . In the present study, we have constructed and expressed fusion proteins comprising wild-type and/or E72Q-mutated VDAC1 and analysed a possible dominant-negative effect of this mutation. The results reveal that the E72Q-VDAC1 mutant imposes its effect in a dominant-negative manner, abolishing the protective effect of RuR against apoptotic cell death.
EXPERIMENTAL

Materials
Hepes, leupeptin, PMSF, sucrose and Tris were purchased from Sigma-Aldrich. RuR (97 % pure) was obtained from Fluka. STS (staurosporine) was obtained from Fermentek Biotechnology. Monoclonal anti-VDAC1 antibodies, prepared against the N-terminal region of 31HL human porin were from Novobiochem. HRP (horseradish peroxidase)-conjugated antimouse and anti-goat antibodies were obtained from Promega. Metafectene was purchased from Biotex. DMEM (Dulbecco's modified Eagle's medium) and the supplements, FBS (fetal bovine serum), L-glutamine, penicillin and streptomycin, were purchased from Biological Industries. Blasticidin was purchased from InvivoGen. MitoTracker Red (chloromethyl-X-rosamine) was from Molecular Probes.
Plasmids and site-directed mutagenesis
rVDAC1 (rat VDAC1) dimeric fusion proteins
The gene encoding the first rVDAC1 unit in the fusion protein, containing the ATG start codon, was modified to include a flexible (Gly 4 -Ser) 3 linker at the C-terminus of the protein. DNA for the second rVDAC1 molecule, containing the whole coding region and the stop codon (TAA), was conjugated at its 5 -end to the linker attached at the 3 -end of the former. The rVDAC1 coding sequence served as a template for PCR of both VDAC1 molecules in the fusion protein. For the first VDAC1 in the fusion protein, we used the primers 5 -GGGGTACCATG-GCTGTGCCACCCACGTATGCCGAT-3 (forward 1) and 5 -CGGGATCCGCCGCCGCCGGAGCCGCCGCCGCCGGAGC-CGCCGCC-3 (reverse 1), which have a KpnI sequence incorporated into the forward primer and a BamHI sequence into the reverse primer. For the second VDAC1 of the fusion protein, we used the primers 5 -CGGGATCCATGGCTGTGC-CACCCACGTATGCC-3 (forward 2) and 5 -GGAGGGCC-CTTATGCTTGAAATTCCAGTCCTAGACCAAGCTT-3 (reverse 2), with a BamHI sequence incorporated into the forward primer and a SmaI sequence into the reverse primer. Each PCR product was subcloned into the pGEM-T Easy vector (Invitrogen).
To introduce the E72Q mutation, to obtain the E72Q-rVDAC1-rVDAC1, rVDAC1-E72Q-rVDAC1 or E72Q-rVDAC1-E72Q-rVDAC1 fusion proteins, we used the QuikChange TM sitedirected mutagenesis kit (Stratagene). Each VDAC1 sequence of the dimeric fusion protein (separately subcloned in pGEM-T Easy vectors) served as template for wholeplasmid PCR enhancement, using the following primers: 5 -GGCTGACGTTTACTCAGAAGTGGAACACAG-3 and 5 -CTGTGTTCCACTTCTGAGTAAACGTCAGCC-3 .
The second VDAC1 of the fusion protein (either a wild-type or E72Q mutant) was excised out of its pGEM-T Easy vector and subcloned into a pGEM-T Easy vector encoding the first VDAC1 (either a wild-type or E72Q mutant) using SacII/ BamHI restriction enzymes. The different VDAC1-VDAC1 fusion proteins encoded in pGEM-T Easy vectors were sequenced and subcloned into the KpnI/NotI sites of the tetracyclineinducible pcDNA4/TO vector (Invitrogen). In this manner, we constructed the following fusion proteins: rVDAC1-rVDAC1 (V-V); rVDAC1-E72Q-rVDAC1 (V-E72QV); E72Q-rVDAC1-rVDAC1 (E72QV-V); and E72Q-rVDAC1-E72Q-rVDAC1 (E72QV-E72QV). DNA encoding E72Q-rVDAC1-rVDAC1 and E72Q-rVDAC1-E72Q-rVDAC1 were subcloned into the NotI/NotI sites of the pcDNA4/TO vector, due to low efficiency of the KpnI restriction enzyme.
Plasmids
To create pcDNA4/TO-rVDAC1, the pcDNA4/TO-rVDAC1-rVDAC1 was digested with BstXI (a unique restriction site inside the rVDAC1-coding sequence) and transformed into Escherichia coli. To create the pcDNA4/TO-E72Q-rVDAC1 plasmid DNA, encoding the second E72Q-mutated rVDAC1 of the fusion protein, the pGEM-T Easy vector was digested with BamHI/NotI and subcloned into the pcDNA4/TO plasmid.
pcDNA4/TO-rVDAC1-rVDAC1, containing an TEV (tobacco etch virus) protease recognition site, was created by introducing the recognition site (ENLYFQG) in-frame between the two VDAC1 molecules of the fusion protein. This was achieved by using two oligonucleotides encoding the DNA sequence of the protease recognition site with BamHI overhangs at the 3 -and 5 -ends as follows: TEV-(F), 5 -GATCCGAAAATCTGTATTTCCAGGGCG-3 and TEV-(R), 5 -GATCCGCCCTGGAAATACAGATTTTCG-3 (the TEV recognition site is underlined, between the BamHI overhangs), which were annealed. The pcDNA4/TO rVDAC1-rVDAC1 plasmid was cleaved with BamHI (a unique restriction enzyme site in the linker sequence between the two VDAC1-encoding genes) and the annealed TEV recognition site was subcloned in this region (V-T-V).
To create the pcDNA4/TO-rVDAC1-rVDAC1-GFP plasmid, DNA encoding the second VDAC1 molecule of the fusion protein, subcloned in the pGEM-T Easy vector, was digested with BamHI/EcoRI restriction enzymes to obtain insert 1. Plasmid pcDNA4/TO-rVDAC-GFP [encoding rVDAC1-GFP (green fluorescent protein)] was digested with EcoRI/NotI restriction enzymes, resulting in insert 2. These two inserts were subcloned into the pcDNA4/TO-rVDAC1-rVDAC1 plasmid that had been cleaved with BamHI/NotI, in a triple ligation process (V-V-GFP).
To generate dimeric VDAC1 for subsequent expression and purification, the rVDAC1-rVDAC1 DNA sequence was cloned into the pYES2 plasmid, which was then introduced into the M22-2 porin-null yeast strain.
Cell Culture
HEK-293T cells [HEK (human embryonic kidney)-293 cells expressing the large T-antigen of SV40 (simian virus 40)] and TREx-293 (HEK-293 cells that express the tetracycline repressor)
were grown in DMEM supplemented with 10 % (v/v) FBS, 2 mM L-glutamine, 1000 units/ml penicillin and 1 mg/ml streptomycin. T-REx-293 cells were grown in presence of 5 μg/ml blasticidin. Cells were maintained in a humidified 5 % CO 2 atmosphere at 37
• C.
Cell transfection
Using metafectene (according to the manufacturer's instructions), T-REx-293 cells were transiently transfected with plasmid pcDNA4/TO encoding rVDAC1, E72Q-rVDAC1, rVDAC1-rVDAC1, rVDAC1-E72Q-rVDAC1, E72Q-rVDAC1-rVDAC1 or E72Q-rVDAC1-E72Q-rVDAC1 and grown for 120 h in the presence of 1 μg/ml tetracycline. The cells were incubated with 1 μM RuR for 18 h prior to exposure to 1.25 μM STS for 5 h. Overexpression of rVDAC1 or the various versions of dimeric rVDAC1 was induced by 2.5 μg/ml tetracycline for 99 h. RuR (1 μM) treatment lasted for 18 h prior to the cell death analysis, which was conducted by staining with Acridine Orange and ethidium bromide. For calcium-phosphate-based transfection, cells (3 × 10 5 ), seeded on to 60-mm-diameter culture dish plates, were grown in 5 ml of DMEM, supplemented with 10 % (v/v) FBS, 2 mM L-glutamine, 1000 units/ml penicillin and 1 mg/ml streptomycin. Plasmid DNA (2 μg) was added to 250 μl of sterile 240 mM CaCl 2 and then mixed with 250 μl of sterile Hepes buffer (50 mM Hepes/NaOH, pH 7.05, 280 mM NaCl, 10 mM KCl, 1.5 mM Na 2 HPO 4 · H 2 O and 12 mM glucose). The mixture was applied to HEK-293T cells. The cells were maintained in a humidified 5 % CO 2 atmosphere at 37
• C. The transfection medium was replaced with 3 ml of fresh medium after 18 h.
Apoptosis analysis by staining of cells with Acridine Orange and ethidium bromide
To determine the extent of apoptosis, cells were centrifuged (at 1000 g for 5 min) and subjected to staining with Acridine Orange and ethidium bromide, as described previously [19] . Stained cells were visualized by fluorescence microscopy (under an Olympus IX51 microscope), in which early and late apoptotic cells were counted. Approx. 300 cells were counted for each treatment.
TEV protease production and treatment
For TEV protease purification, E. coli BL21 bacteria cells, transformed with the plasmid expressing the TEV protease mutant (S219V), were grown with 2 × YT medium (16 g/l tryptone, 10 g/l yeast extract and 5 g/l NaCl) at 37
• C until the attenuance at 600 nm reached 0.5-0.7. Enzyme expression was then induced with the addition of 1 mM IPTG (isopropyl β-D-thiogalactoside). The cells were allowed to grow at 30
• C for 4-5 h and were then harvested by centrifugation (at 5000 g for 5 min), resuspended in lysis buffer (50 mM NaH 2 PO 4, pH 8, 100 mM NaCl, 20 mM imidazole, 0.02 % NaN 3 , 5 mM 2-mercaptoethanol, 10 μM E64 and 1 mM PMSF), using 15-20 ml of buffer for 1 g of pelleted bacteria, and sonicated for a total of 4 min total with 20 s intervals using a Sonic Vibra-Cell Model CV 33 sonicator at 50-60 % amplitude. Next, the sonicated bacteria were centrifuged (at 18 000 g for 30 min) and the supernatant was filtered using a 0.45 μm filter (Millipore). The resulting filtrate was loaded on to a 5 ml HiTrap TM chelating HP Ni-NTA (Ni 2+ -nitrilotriacetate) column and eluted with a linear gradient elution buffer (50 mM NaH 2 PO 4 , pH 8, 100 mM NaCl, 0.02 % NaN 3 , and 20 to 500 mM imidazole) via FPLC with an AKTA TM purifier. Two distinct peaks were eluted, with the second peak containing the TEV enzyme. TEV-protease-containing fractions were combined, dialysed at 4
• C overnight (using a Cellu-Sep ® regenerated cellulose tubular membrane with a nominal molecular mass cut-off of 6-8 kDa) against dialysis buffer (50 mM Tris/HCl, pH 7.5, 1 mM EDTA and 5 mM dithiothreitol). The dialysed sample was centrifuged (at 13 000 g for 20 min) and the supernatant containing the purified enzyme was aliquoted, frozen in 50 % (v/v) glycerol and stored at −80
• C. T-REx-293 cells were transfected with plasmid pcDNA4/TO encoding the TEV-inserted rVDAC1-rVDAC1 using metafectene and harvested 72 h post-induction of expression with 2.5 μg/ml tetracycline. Cells (400 μg of protein) were washed with PBS and incubated at 30
• C for 90 min with the 20 μg of the purified recombinant TEV protease in buffer [50 mM Tris/HCl, pH 8, 0.05 mM EDTA, 0.1 M NaCl, 12 μg/ml digitonin (for cell permeabilization), 1 mM dithiothreitol, 2.5 μg/ml leupeptine and 0.15 mM PMSF] in a total reaction volume of 200 μl. To obtain the membrane and cytosolic fractions, cells were disrupted in a glass/Teflon homogenizer on ice (approx. 15 strokes) and centrifuged (at 1000 g for 5 min at 4
• C). The supernatants were recentrifuged (15 000 g for 15 min at 4
• C), with the final supernatant representing the cytosolic fraction and the pellet representing the membrane fraction. Both membrane and cytosolic fractions were subjected to SDS/PAGE and Western blotting using anti-VDAC1 antibodies.
Cross-linking experiments
T-REx-293 cells were transfected with plasmid pcDNA4/TOrVDAC1-rVDAC1 or pcDNA4/TO-rVDAC1 using metafectene. After 72 h of growth in the presence of 2.5 μg/ml tetracycline, cells were exposed to 1.25 μM STS for 2.5 h and then harvested (1000 g for 5 min). The cells (600 μg) were incubated at 30
• C for 20 min (in a total reaction volume of 200 μl) in PBS (pH 8.3) containing 300 μM EGS [ethylene glycol bis(succinimidyl succinate)] dissolved in 50 % (v/v) DMSO (the final DMSO concentration in EGS-treated and control cells was less than 1 %). Cross-linking was terminated by the addition of lysine to a final concentration of 5 mM. After 5 min of incubation at room temperature (25 • C), cells were lysed and subjected to SDS/PAGE and immunoblotting using the anti-VDAC1 antibody.
Cell imaging by confocal microscopy
HEK-293T cells (3 × 10 5 ) were grown on poly-D-lysine-coated coverslips in a 60-mm-diameter dish and transfected with plasmid pcDNA4/TO encoding rVDAC1-rVDAC1-GFP or rVDAC-GFP using CaHPO 4 
Purification of VDAC
For recombinant VDAC purification, rVDAC1 and rVDAC1-rVDAC1 were expressed in the Saccharomyces cerevisiae por1-null strain M22-2 [19] and purified directly from the yeast cells as described previously for VDAC purification from rat liver mitochondria [4] . Yeast cells were broken using glass beads, centrifuged (at 20 000 g for 30 min), resuspended in 10 mM Tris/HCl, pH 7.2, containing protease inhibitors, incubated with 2 % (w/v) LDAO (N,N-dimethyldodecylamine-N-oxide) at 4
• C for 20 min followed by centrifugation (at 20 000 g for 30 min) and the obtained supernatant was loaded on to a dry celite/hydroxyapatite (2:1) column. VDAC was eluted with a solution containing 10 mM Tris/HCl, pH 7.2, 2 % (w/v) LDAO, 50 mM NaCl and 22 mM NaH 2 PO 4 .
VDAC channel reconstitution, recording and analysis rVDAC1 and rVDAC1-rVDAC1 expressed and purified from yeast, were reconstituted into a PLB (planar lipid bilayer). Singlechannel current recording and data analysis were performed as described previously [39] . Briefly, the PLB was prepared from soya bean asolectin dissolved in 50 mg/ml n-decane. Purified VDAC1 was added to the chamber defined as the cis side. After one or a few channels inserted into the PLB, excess protein was removed by washing the cis chamber with 20 volumes of solution to prevent further incorporation. Currents were recorded under voltage-clamp using a Bilayer Clamp BC-535B amplifier (Warner Instruments) and measured with respect to the trans side of the membrane (ground). The currents were low-pass-filtered at 1 kHz and digitized on-line using a Digidata 1440-interface board and PCLAMP 10.2 software (Axon Instruments).
Gel electrophoresis and immunoblotting analysis
SDS/PAGE was performed according to Laemmli [40] with 10 % gels. For immunostaining, membranes containing electrotransferred proteins were blocked with 5 % (w/v) non-fat dry milk powder and 0.1 % Tween 20 in Tris-buffered saline, incubated with monoclonal anti-VDAC antibodies (1:10 000) and then with alkaline-phosphatase-conjugated anti-(mouse IgG) or HRPconjugated anti-(mouse IgG) secondary antibodies (1:10 000). Antibody binding was detected using enhanced chemiluminiscent substrate (Pierce) for detection of HRP.
Figure 1 RuR protects against apoptosis induced by various reagents in cells expressing mVDAC1 but not E72Q-mVDAC1
T-REx-293 cells expressing shRNA-hVDAC1 were transfected with a plasmid encoding wild-type or E72Q-mutated mVDAC1. mVDAC1 expression was induced by adding 1 μg/ml tetracycline. At 3 days after the tetracycline addition, cells expressing wild-type mVDAC1 (black bars) or E72Q-mVDAC1 (grey bars) in the absence or presence of 2 μM RuR (white and hatched bars respectively), were exposed to 60 μM curcumin or 10 μM 
RESULTS
In our previous studies [18, 19, 41] , we identified a single-point mutation in the VDAC1 protein, i.e. replacement of Glu 72 with a glutamine residue, that modified the interaction of the protein with the anti-apoptotic effectors, Bcl2, HK-I and RuR, abolishing their anti-apoptotic effects. As shown in Figure 1 , RuR protected against apoptotic cell death as induced by various stimuli in cells expressing wild-type but not E72Q-mVDAC1. The loss of a RuR-mediated anti-apoptotic effect was obtained upon expression of mutated VDAC1 in cells also expressing endogenous VDAC1, suggesting that the mutation displays a dominant-negative effect. To further address the dominantnegative effect of E72Q-rVDAC1, we constructed dimeric VDAC1 fusion proteins composed of wild-type and/or E72Q-mutated rVDAC1, and tested the anti-apoptotic effect of RuR in cells expressing these VDAC1 fusion proteins. Furthermore, we employed the E72Q-rVDAC1-containing dimeric protein to address the function of VDAC1 oligomerization in apoptosis. Four dimeric fusion proteins composed of wild-type and/or mutated VDAC1 linked by a long and flexible linker peptide, (Gly 4 -Ser) 3 , between the two proteins were constructed, namely rVDAC1-rVDAC1, rVDAC1-E72Q-rVDAC1, E72Q-rVDAC1-rVDAC1 and E72Q-rVDAC1-E72Q-rVDAC1. All were successfully expressed in T-REx-293 cells (Figure 2A) .
To confirm that the rVDAC1-rVDAC1 fusion protein was localized to mitochondria, we constructed rVDAC1-rVDAC1-GFP, expressed it in cells ( Figure 2B ) and visualized its intracellular distribution in comparison with the mitochondrial marker, MitoTracker Red ( Figure 2C ). As with rVDAC1-GFP expression, rVDAC1-rVDAC1-GFP also showed punctuated
Figure 2 Expression of rVDAC1-rVDAC1 chimaeras and mitochondria localization of the rVDAC1-rVDAC1-GFP fusion protein
(A) Plasmids encoding the monomeric wild-type (V) and mutant protein (E72QV), and the four fusion proteins, rVDAC1-rVDAC1 (V-V), rVDAC-E72Q-rVDAC1 (V-E72QV), E72Q-rVDAC1-rVDAC1 (E72QV-V) and E72Q-rVDAC1-E72Q-rVDAC1 (E72QV-E72QV), were constructed, cloned into the tetracycline-inducible pcDNA4/TO vector and expressed in T-REx-293 cells, as described in the Experimental section. After 99 h of induced expression with 1 μg/ml tetracycline, the cells were lysed, and subjected to SDS/PAGE and immunoblotting using anti-VDAC1 antibodies. The molecular mass of the proteins is indicated on the right-hand size. (B) HEK-293T cells were transfected with plasmids expressing GFP, rVDAC1-GFP or rVDAC1-rVDAC1-GFP (V-VGFP). At 48 h post-transfection, the cells were harvested, lysed and subjected to SDS/PAGE and immunoblotting using anti-GFP (left-hand panel) and anti-VDAC antibodies (right-hand panel). The molecular mass of the proteins is indicated. (C) The cells indicated in (B) were grown on coverslips, stained with 25 nM MitoTracker Red and visualized with confocal microscopy, as described in the Experimental section. Scale bar = 5 μm.
distribution that co-localized with MitoTracker Red, suggesting a mitochondrial localization of the rVDAC1-rVDAC1-GFP fusion protein.
Next, to demonstrate that the dimeric rVDAC1-rVDAC1 functions as a channel-forming protein, the protein was expressed in the mitochondria of porin-null yeast, purified ( Figure 3D ) and reconstituted into a PLB. Single-channel recording of reconstituted wild-type VDAC1 ( Figure 3B ) gave a maximal conductance of approx. 4 nS (at 1 M NaCl), whereas dimeric rVDAC1-rVDAC1 showed a higher minimal current unit of 70 pA (at 1 M NaCl and 10 mV) ( Figure 3A) , representing a maximal conductance of approx. 7 nS. Reconstituted dimeric rVDAC1-rVDAC1 showed the typical (normal) voltagedependence conductance, with the highest values being obtained at transmembrane potentials between −20 and +20 mV, and decreasing at both high negative and positive potentials ( Figure 3C) ; at voltages higher than + − 40 mV, the current was increased, but the membrane became unstable with increased leaking. RuR interacted with the dimeric protein and decreased its channel conductance, as with wild-type VDAC1 (Figures 3A and  3B ). It should be noted that the PLB-reconstituted dimeric protein showed a noisy current, which was stabilized upon exposure to RuR ( Figure 3A) . These results indicate that both rVDAC1 molecules in the chimaeric protein were inserted into the bilayer as active channels with RuR sensitivity, and are correctly folded.
Next, we tested the ability of the VDAC1 dimeric fusion proteins to induce cell death upon their overexpression. As with rVDAC1 and E72Q-rVDAC1, overexpression of each of the fusion proteins in T-REx-293 cells resulted in cell death ( Figure 4A ). As E72Q-rVDAC1 is insensitive to RuR, the effects of RuR on cell death induced by overexpression of the various wild-type and mutated rVDAC1 and fused rVDAC1-rVDAC1 proteins were tested. As shown previously [19] , RuR protected against cell death in cells expressing wild-type but not mutated E72Q-rVDAC1. Protection against cell death was also obtained in cell expressing rVDAC1-rVDAC1 ( Figure 4A ). However, no protection against apoptosis was obtained with RuR in cells expressing the fused VDAC1 proteins containing the E72Q mutation. In contrast with the expected result, of partial protection by RuR, when only one of the two VDAC1 molecules in the fusion protein carried the mutation, complete insensitivity of the rVDAC1-E72Q-rVDAC1 or E72Q-rVDAC1-rVDAC1 heterodimers to RuR was observed ( Figure 4A ). These results suggest that the fusion protein is functional in cell death and that the dominant-negative effect of the E72Q mutation persists in the dimeric fusion protein. These results also show that although the cells express endogenous hVDAC1, the presence of the rVDAC1 mutants completely prevented the anti-apoptotic effect of RuR.
The dominant-negative effect of the E72Q mutation in VDAC1 was also observed when apoptosis was induced by STS ( Figure 4B ). RuR conferred no protection against STS-induced cell death when either of the VDAC1 molecules in the dimeric fusion protein contained the E72Q mutation.
The finding that the E72Q mutation exerts its insensitivity to RuR-mediated inhibition of apoptosis, regardless of its location in the VDAC1 heterodimer, i.e. either as the N-terminal or Cterminal partner of the dimeric molecule, indicates that both monomers in the fusion protein are functional. In addition, the finding that the insensitivity to RuR in the heterodimers was not partial, but in fact complete, reveals that the mutated monomer is dominant over the non-mutated monomer and thus suggests that the two monomers in the fused protein function as a unit in the complex process of apoptotic cell death.
To assess whether the fusion proteins are completely inserted into the OMM, we constructed a fusion protein in which a TEV protease cleavage site (ENLYFQG) was introduced between the two rVDAC1 monomers of the fusion protein. Cells expressing the VDAC1 dimeric fusion protein with the TEV recognition site separating between the two monomers were exposed to the TEV protease in the presence of digitonin. The cytosolic and membrane fractions were then separated and analysed by immunoblotting using anti-VDAC antibodies ( Figure 5 ). The dimeric fusion protein was indeed cleaved by TEV protease, with two separated VDAC1 monomers generated by the cleavage. One VDAC1 partner, bearing the linker showed higher molecular mass. Additionally, both monomers were found to be embedded in the membrane, as both VDAC1 partners were found in the membrane fraction ( Figure 5) .
Next, we determine whether dimeric rVDAC1-rVDAC1 can undergo oligomerization as does wild-type VDAC [13, 27, 31, 33] . We analysed the oligomeric status of VDAC in cells expressing rVDAC1, dimeric rVDAC1 and in control cells, with or without apoptosis induction by STS. The effects of apoptosis induction in cells expressing rVDAC1 or the rVDAC1-rVDAC1 fusion protein on the oligomeric state of VDAC were analysed by exposing the cells to the chemical cross-linking reagent EGS to stabilize any VDAC oligomers formed. Figure 6 clearly indicates that oligomerization of VDAC1 in the transfected cells is increased in response to apoptosis stimulus. Moreover, rVDAC1-rVDAC1 forms high oligomeric states with or without STS-induced apoptosis, results which are in agreement with the observed induction of apoptosis upon overexpression of VDAC1 [19] or of the fusion protein ( Figure 4A ). Interestingly, small numbers of VDAC1 hexamers were obtained in cells expressing the rVDAC1-rVDAC1 fusion protein, even without chemical cross-linking with EGS and after subjecting the samples to boiling in the presence of SDS, followed by SDS/PAGE, suggesting a possible equilibrium shift towards the formation of stable VDAC1 oligomers. The results indicate that dimeric rVDAC1-rVDAC1 can undergo oligomerization as does wild-type VDAC [13, 27, [31] [32] [33] .
DISCUSSION
In the present study, we have genetically engineered dimeric fusion rVDAC1 proteins comprising wild-type and E72Q-mutated versions to provide direct evidence for a dominant-negative effect of E72Q-rVDAC1. This mutant does not bind RuR or HK, and hence, in cells expressing the E72Q-rVDAC mutant, there is no protection by these agents against apoptosis, as induced by various means [10, 18, 19] . We demonstrated that a single mutation in one of the partners in the rVDAC1-rVDAC1 fusion protein was sufficient to diminish the protective anti-apoptotic effect of RuR. Moreover, the results indicate that functional interactions between VDAC1 monomers in the oligomeric protein are involved in apoptotic cell death.
The recombinant dimeric rVDAC1-rVDAC1, as the monomeric protein, is embedded in the mitochondrial membrane and functions as a channel
The results showed that the rVDAC1-rVDAC1-GFP distribution, and that of recombinant rVDAC1, overlaps with the mitochondrial marker MitoTracker Red, suggesting mitochondrial localization T-REx-293 cells were transfected to express the TEV-site-containing rVDAC1-rVDAC1 dimer (V-T-V) upon induction with 2.5 μg/ml tetracycline. After 70 h, the cells were harvested and incubated at 30 • C for 1.5 h with purified TEV protease in a buffer containing 12 μg/ml digitonin (for cell permeabilization) as described in the Experimental section. Cells were homogenized separated into membrane and cytosolic fractions. The (A) total lysate and (B) the membrane fraction were subjected to SDS/PAGE and Western blotting using the anti-VDAC antibodies. VDAC1 was not detected in the cytosolic fraction (results not shown). VDAC-linker indicates the position of VDAC1 connected to the intersubunit linker. ( Figure 2 ). In addition, the TEV protease cleavage-based approach indicates that the two rVDAC1 molecules in the rVDAC1-rVDAC1 fusion protein are embedded in the membrane ( Figure 5 ). These results suggest that the dimeric fusion protein structure is probably defined as two properly folded monomers, which are localized to the OMM. This is highly supported by the finding that the dimeric rVDAC1-rVDAC expressed and purified from porinnull yeast, is able to form a channel with voltage dependence and sensitivity to RuR similar to those of monomeric VDAC1, suggesting that the dimer is correctly folded form and is inserted into the membrane (Figure 3) . Moreover, overexpression of rVDAC1-rVDAC1 fusion proteins, as with monomeric rVDAC1, triggered RuR-sensitive apoptotic cell death ( Figure 4A ). This supports the idea that the VDAC1 fusion protein maintained its structure and ability to induce apoptosis. These findings, however, do not imply that the transport activity of VDAC1 in the regulation of metabolic and energetic functions of mitochondria involves a dimeric form of VDAC1.
Our results are in agreement with several studies in which dimeric fusion channel proteins were used to address the question of the functional protein unit. Indeed, great success has been achieved in the design and application of engineered fused proteins, such as with the K + channels (TASK-1/TASK-3 and leak channels) [42, 43] , KCNK (subfamily K channel) [44] and ADP/ATP carrier 2 [45] , all of which were found to be active in the fused form.
The dominant-negative effect of E72Q-rVDAC1 in a rVDAC1-rVDAC1 fusion protein and the function of VDAC1 oligomers in apoptosis RuR was shown to inhibit cytochrome c release and activation of caspase 3 by curcumin [37] , or STS-induced apoptosis in the U-937 cell line [19] . RuR also inhibits both ursolic-acid-induced cell death in LH-60 cells [38] , as well as STS-and microcystininduced cell death in cultured rat hepatocytes [36] . The antiapoptotic effect of RuR results from its direct interaction with VDAC1, as reflected by its direct effect on the purified VDAC1 channel and its inability to protect against apoptosis in cells expressing mutated VDAC1 [10, 18, 19] . The specific VDAC1 mutation E72Q, inhibited the interaction of RuR with bilayerreconstituted VDAC1 in vitro and abolished RuR-mediated protection against cell death induced by STS or overexpression of VDAC1 in vivo [10] . The E72Q mutation, which interrupts the interaction between VDAC1 and HK or RuR, was also found to induce an increase in mitochondrial swelling and oxidative phosphorylation activity, as well as reduction in mitochondrial membrane cholesterol levels [46] .
According to the recently established hVDAC1 threedimensional structure, Glu 72 (Glu 73 when counting the first methionine residue) plays an important role in the conformational instability of the first four or five β-strands at the N-terminal of the VDAC1 barrel due to the break in the amphipathic pattern in strand β4 introduced by Glu 73 [23] . Replacing the charged Glu 73 with a glutamine [10, 18, 19] or valine [23] residue resulted in the β-barrel becoming more stable [23] . Moreover, Glu 72 plays an important role in the structural arrangement of the VDAC1 barrel and the N-terminal 25 residues of VDAC1, regions that assume different positions in different VDAC1 conformations [23] . The function of the Glu 72 in conferring a certain conformation on VDAC1 is reflected in the inability of E72Q-VDAC1 to bind HK [47] , Bcl2 [41] or RuR [5, 10, 19] . Furthermore, it is not only replacement of Glu 72 with a glutamine [5, 10, 19] or valine [23] residue, but also its chemical modification with DCCD (dicyclohexylcarbodi-imide), that altered the protein such that it does not bind HK [48] . These previous results, together with the finding that the E72Q mutation abolished the protection against apoptosis mediated by RuR (Figures 4A and 4B ; [10, 18, 19] ), suggests that this mutation is stabilizing a VDAC1 conformation that is not recognized by RuR.
Our results also show that a dimeric VDAC1 fusion protein consisting of one E72Q mutant monomer and a wild-type VDAC1 partner still abolished the ability of RuR to protect against apoptosis, indicating that two or more VDAC1 units are involved in the RuR-VDAC1 interaction and hence in mediating the antiapoptotic effect of RuR. In the absence of such a dominantnegative effect, we would have expected 50 % or less protection against apoptosis mediated by RuR in cells expressing the E72Q-rVDAC1-rVDAC1 heterodimer, assuming each channel functions separately. However, we found that a chimaeric dimer consisting of one E72Q mutant monomer and a wild-type VDAC1 partner still abolished the protective effect of RuR, as does monomeric E72Q-rVDAC1 or dimeric E72Q-rVDAC1-E72Q-rVDAC1 ( Figures 4A and 4B) . Thus the chimaeric protein rVDAC1-rVDAC1 carrying the mutation E72Q in either of its partner molecules, exhibits the functional behaviour of the mutated protein. The inability of RuR to protect against cell death in cells expressing E72Q-rVDAC1 might result from a RuR interaction with two VDAC1 molecules. Therefore intermolecular interactions between at least two different VDAC1 molecules mediate the anti-apoptotic effect of RuR. This, however, does not necessarily imply that RuR is incapable of separately inhibiting each monomeric VDAC1 in the fusion protein. Such an interaction, however, did not mediate the anti-apoptotic effect of RuR, but rather inhibited VDAC channel activity [4, 10] .
The dominant-negative effect of E72Q-rVDAC1 demonstrated in this study supports the suggestion that oligomeric VDAC1 is the functional unit in apoptosis, i.e. that it is involved in the proteinconducting channel that mediates the release of pro-apoptotic proteins during apoptosis [13, 27, 49] . Chemical cross-linking experiments in cells expressing VDAC1-VDAC1 fusion proteins showed that this fusion protein undergoes oligomerization while maintaining its protein-protein interacting ability. VDAC1-VDAC1 also forms a minor amount of stable VDAC1 hexamers without induction of apoptosis via STS. The low level of VDAC1 hexamers observed in cells expressing the VDAC1-VDAC1 fusion protein, even without chemical cross-linking with EGS and following SDS/PAGE, suggests a possibly equilibrium shift towards the formation of stable hexamers. Similar results were demonstrated with VDAC1 reconstituted into cytochromec-encapsulated liposomes [27] , which formed VDAC dimers, tetramers and multimers in the absence of cross-linking reagents after subjecting the samples to boiling in the presence of SDS, followed by SDS/PAGE. Thus RuR does not prevent VDAC oligomerization but rather interferes with the activity of the oligomer in apoptosis. RuR, due to its hexameric positive charges, can bind to two or more different sites in VDAC, which may be located in two different associated VDAC1 molecules. Indeed, RuR was shown to interact with two molecules of the TASK-1 and TASK-3 two-pore domain potassium channel subunits [43] . Similarly, we have shown that RuR binds to two different sites in VDAC which may be located in two different, yet associated VDAC1 molecules [10] . The RuR interaction with VDAC1 molecules inhibits cytochrome c release and subsequent apoptosis. However, upon expression of the mutated E72Q-VDAC1 [5, 10, 19] or the heterodimer E72Q-VDAC1-VDAC1, RuR is unable to bind to the mutated protein and is, thereby, unable to cross-link two or more VDAC1 molecules and block the mega-pore.
In summary, this study further supports the involvement of the VDAC1 oligomeric state in apoptosis [13, 27, 49] and, hence in the mitochondrial death machinery.
